News
When Pascal Soriot flew in to speak at the Boao Forum in China this year, many expected him to keep a low profile. With ...
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
Cambridge UK Pharma giant AstraZeneca is proving a variation on the proverbial enigma as it ponders the most appreciative ...
AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...
Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...
Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback